SavedAdd your journal

Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 10

Does short-term montelukast treatment cause sleep problems or psychiatric problems in children? A preliminary study

Işıl ÇAKMAK KARAER
Yunus Emre DÖNMEZ
Pages
2654–2660
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Long-term follow-up studies with high numbers of participants are needed to test these results and evaluate the possible neuropsychiatric side effects of long-term montelukast use.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Montelukast is one of the treatment choices for symptomatic allergic rhinitis and asthma in children.
📊
Key Findings & Data:The aim of this study was to investigate the effect of short-term montelukast use on children's sleep habits, and whether sleep-related problems and psychiatric problems may occur.Material and Methods: This prospective study was conducted with 30 children.
💡
Conclusion & Impact:Long-term follow-up studies with high numbers of participants are needed to test these results and evaluate the possible neuropsychiatric side effects of long-term montelukast use.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Montelukast is one of the treatment choices for symptomatic allergic rhinitis and asthma in children. Various researches emphasized that montelukast use causes neuropsychiatric side effects. The aim of this study was to investigate the effect of short-term montelukast use on children's sleep habits, and whether sleep-related problems and psychiatric problems may occur.Material and Methods: This prospective study was conducted with 30 children. Psychiatric disorders and symptoms, sleep habits, sleep-related problems were evaluated before the use of montelukast. All of these evaluations were repeated at 4th and 8th week of treatment. Psychiatric assessment was performed with the Schedule for Affective Disorders and Schizophrenia for School Age Children-Present and Lifetime Version – Turkish. Sleep habits, sleep-related problems were assessed using the Children Sleep Habits Questionnaire Short Form (CSHQ-S) and the Pediatric Sleep Questionnaire (PSQ).Results: According to the psychiatric assessment, no psychiatric disease or symptom was identified before treatment and at the 4th and 8th week of treatment. The CSHQ-S and PSQ responses were evaluated and there was no significant difference between results obtained before treatment and at the 4th and 8th weeks of treatment.Conclusion: The results revealed that short-term montelukast use is safe and do not cause changes sleep habits, sleep-related problems or psychiatric problems in children. Long-term follow-up studies with high numbers of participants are needed to test these results and evaluate the possible neuropsychiatric side effects of long-term montelukast use.

🔖

Cite This Article

KARAER, I. Ç., DÖNMEZ, Y. E. (2022). Does short-term montelukast treatment cause sleep problems or psychiatric problems in children? A preliminary study. Annals of Medical Research, Cilt: 27 - Sayı: 10, 2654–2660. https://ajindex.com/articles/446349

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006;36:689–703
  2. Yilmaz O, Altintas D, Rondon C, Cingi C, Oghan F. Effectiveness of montelukast in pediatric patients with allergic rhinitis. Int J Pediatr Otorhinolaryngol 2013;77:1922-4
  3. Calapai G, Casciaro M, Miroddi M, Calapai F, Navarra M, Gangemi S. Montelukast-induced adverse drug reactions: a review of case reports in the literature. Pharmacology 2014;94:60-70
  4. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization. GA(2)LEN and AllerGen). Allergy 2008;63:8–160
  5. Bousquet J, Demoly P, Humbert M. Montelukast in guidelines and beyond. Adv Ther 2009;26:575–87
  6. Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001;31:77–87
  7. Haarman MG, van Hunsel F, de Vries TW. Adverse drug reactions of montelukast in children and adults. Pharmacol Res Perspect 2017;5:e00341
  8. US Food and Drug Administration: Transcript of Singulair presentation, FDA Pediatric Advisory Committee Meeting. https:/www.fda.govdownloads/ ScienceResearch/SpecialTopicsPediatricTherapeutics Research / UCM434618.pdf access date 20.11.2019 9. European Medicines Agency: Opinion of the paediatric committee on the acceptance of a modification of an agreed paediatric investigation plan. https:// www.ema.europa.eu/en/documents/pip-decision/ p/200/2009-european-medicines-agency-decision- 1-october-2009-acceptance-modification-agreedpaediatric_ en.pdf access date 20.11.2019 10. Perona AA, García-Sáiz M, Álvarez ES. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase®. Drug Saf 2016;39:69-78
  9. Schumock GT, Stayner LT, Valuck RJ, Joo MJ, Gibbons RD, Lee TA. Risk of suicide attempt in asthmatic children and young adults prescribed leukotrienemodifying agents: a nested case-control study. J Allergy Clin Immunol 2012;130:368–75
  10. Ali MM, O'Brien CE, Cleves MA, Martin BC. Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case‐control study. Pharmacoepidemiol Drug Saf 2015;24:435-45
  11. Wallerstedt SM, Brunlöf G, Sundström A, Eriksson AL. Montelukast and